Profile Response Detail

Molecular Profile KRAS G12S
Therapy Erlotinib
Indication/Tumor Type lung adenocarcinoma
Response Type no benefit
Create By cstatz
Update By cstatz

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS G12S lung adenocarcinoma no benefit Erlotinib Preclinical - Cell line xenograft Actionable In a preclinical study, lung adenocarcinoma cells harboring KRAS G12S were insensitive to treatment with Tarceva (erlotinib) in culture, demonstrating no change in Erk, Mek, and Akt activity and minimal inhibition of cell growth (PMID: 29925635). 29925635
PubMed Id Reference Title Details
(29925635) Afatinib restrains K-RAS-driven lung tumorigenesis. Full reference...